First DS1025 dose administered in international Phase 1 solid-tumor trial
Kansai Medical University Hospital gave the first worldwide dose of investigational CD25-directed antibody drug conjugate DS1025 in a global Phase ...
Tag: Daiichi Sankyo
POPULAR NEWS
-
![Study identifies histidine ‘pendulum’ mechanism underlying high activity of Group A [FeFe]-hydrogenases](https://bioengineer.org/wp-content/uploads/2026/10/stackrss-featured-13116-350x250.png)
Study identifies histidine ‘pendulum’ mechanism underlying high activity of Group A [FeFe]-hydrogenases
-
First DS1025 dose administered in international Phase 1 solid-tumor trial
-
Johns Hopkins-led protein-misfolding research protocol receives up to $52.1 million
-
Experimental study reports ordered polar vortices in lead-free BaTiO3/SrTiO3 superlattices on silicon